Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18689166 | 0.85 | UCHL1 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL31258190 | 0.84 | USP30 (0.40) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL31710740 | 0.81 | USP30 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL3709336 | 0.76 | USP30 (0.38) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL29821684 | 0.76 | USP30 (0.38) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL30293091 | 0.75 | USP30 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL22438298 | 0.75 | USP30 (0.39) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL15412342 | 0.74 | USP30 (0.40) | UCHL1USP30ELANEFFAR1DGAT1 | |
| SCHEMBL31531676 | 0.73 | ELANE (0.41) | ELANENR1H2FAAH | |
| SCHEMBL32684434 | 0.72 | USP30 (0.36) | UCHL1USP30FFAR1DGAT1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698529-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20240360139-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. | 2024-10-31 | — | — | US | disclosed |
| WO-2024220173-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360139-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | ROCK2, ROCK1, MYLK3 | UCHL1 3184/4885USP30 3342/4885ELANE 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.